Enbrel approved as novel therapy for treatment of psoriasis
- United Arab Emirates: Tuesday, May 10 - 2005 at 16:47
- PRESS RELEASE
Wyeth Pharmaceuticals today announced that Enbrel (etanercept), a novel biologic treatment for rheumatoid arthritis, has received formal approval from the European Union (EU) and the FDA for the treatment of adults with moderate to severe plaque psoriasis, the most common form of psoriasis affecting nearly 80 percent of the psoriasis patients.
ENBREL has been used by more than 280,000 patients worldwide across multiple indications and offers an efficacy and safety profile established over ten years of clinical trials.
Psoriasis is a potentially serious and disabling chronic skin condition that is estimated to affect about 2 percent of the world's population. The percentages for the UAE are alarmingly higher and currently stand at nearly 4.3 percent of the total population.
"Current treatment for psoriasis are often limited, and people with the disease need new treatment options that can provide consistent relief from painful symptoms and can improve their quality of life" said Dr. Hussein Abdel Dayem, Chief Dermatologist- Mafraq Hospital.
Highlighting the effectiveness of Enbrel, Dr. Baher Massoud Medical Director Wyeth Pharmaceuticals Middle East and North Africa, "People with moderate to severe psoriasis treated with Enbrel have experienced rapid relief of symptoms, starting from the first week of treatment, and this effect can last for up to 24 weeks".
There is a significant disease burden associated with psoriasis that can present a lifetime of physical and emotional challenges. It may affect work and social relationships and may cause feelings of depression and emotional embarrassment deeply impacting the quality of life." Said, Dr. Dayem.
Dr. Massoud concluded, "Enbrel has been shown to help manage the potentially painful and visible symptoms of psoriasis, even among patients who have failed other therapies".
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / 4C. AME Info FZ LLC / 4C is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.